Structure Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Cash & Equivalents	129.79	26.09	105.31	16.35
Short-Term Investments	337.53	64.75	2	21.09
Cash & Cash Equivalents	467.32	90.84	107.31	37.45
Cash Growth	414.44%	-15.34%	186.57%	-
Other Current Assets	6.29	2.25	1.94	0.97
Total Current Assets	473.61	93.09	109.25	38.42
Property, Plant & Equipment	8.36	1.29	1.79	0.28
Other Long-Term Assets	0.05	3.46	0.11	0.01
Total Long-Term Assets	8.41	4.76	1.91	0.29
Total Assets	482.02	97.85	111.16	38.7
Accounts Payable	4.74	6.01	3.48	1.53
Current Debt	1.44	0.26	0.35	0.15
Other Current Liabilities	18.56	6.74	4.83	1.37
Total Current Liabilities	24.74	13.01	8.66	3.04
Long-Term Debt	4.01	0	0.27	0.13
Other Long-Term Liabilities	0.3	0	0	0
Total Long-Term Liabilities	4.31	0	0.27	0.13
Total Liabilities	29.05	13.01	8.93	3.17
Total Debt	5.45	0.26	0.62	0.28
Debt Growth	1997.31%	-58.13%	121.79%	-
Retained Earnings	-206.57	-116.95	-64.74	-22.95
Comprehensive Income	0.52	-0.11	0	-0
Shareholders' Equity	452.97	-115.14	-64.74	-22.47
Net Cash / Debt	461.87	90.58	106.69	37.17
Net Cash / Debt Growth	409.90%	-15.10%	187.06%	-
Net Cash Per Share	4.19	9.45	13.10	5.94
Working Capital	448.87	80.08	100.59	35.38
Book Value Per Share	12.33	-36.04	-23.86	-10.77

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).